Category - Developments

Developments

Aurinia Pharma completes enrollment in Phase 3 AURORA trial for LN

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) has completed enrollment for the Phase 3 AURORA trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus...

September 25, 2018

Developments

IntelGenx posts successful bioequivalence study results for RIZAPORT

IntelGenx (TSXV:IGX; OTCQX:IGXT) reported successful results from a bioequivalence study for RIZAPORT, its proprietary anti-migraine VersaFilm product, demonstrating that RIZAORT is bioequivalent to the U.S. reference...

September 24, 2018

Developments

IntelGenx to Partner with Tilray to produce cannabis-infused oral film products

IntelGenx (TSX-V:IGX; OTCQX:IGXT) executed a non-binding letter of intent with Tilray (NASDAQ:TLRY) to co-develop and commercialize oral film products infused with recreational and medical cannabis in anticipation of...

September 20, 2018

Developments

Profound Medical to present TULSA-PRO 3-year outcomes and BPH subgroup analysis

Three-year clinical outcomes and a subgroup analysis of benign prostatic hyperplasia (BPH) patients enrolled in Profound Medical’s (TSX:PRN; OTCQX:PRFMF) earlier Phase 1 safety and feasibility study of TULSA-PRO will be...

September 19, 2018

Developments

CellAegis completes enrollment in heart attack study with autoRIC

Closely-held CellAegis Devices completed enrollment in an investigator sponsored study (FIRST) to evaluate the clinical and economic benefits of remote ischemic conditioning (RIC) therapy in the treatment of patients...

September 11, 2018

Developments

Titan Pharma receives NIDA grant for nalmefene implant to prevent opioid addiction relapse

Titan Pharmaceuticals (NASDAQ:TTNP) was awarded a two-year grant of about $6.7-million from the NIH’s National Institute on Drug Abuse (NIDA) for the development of a ProNeura-based six-month implantable formulation of...

September 10, 2018

Developments

Mati Therapeutics posts positive interim Phase 2 nepafenac results in cataract surgery pain reduction

Closely-held Mati Therapeutics reported encouraging results from a planned interim analysis of an ongoing Phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s Evolute sustained...

September 10, 2018

Developments

Ortho RTi in pact with CMO to manufacture cGMP quantities of Ortho-R

Ortho Regenerative Technologies (CSE:ORTH) entered into an agreement with a leading contract manufacturing organization operating within the global biopharmaceutical industry to begin work on providing Ortho RTi with...

September 6, 2018

Developments

Titan, Nevada Center for Behavioral Health collaborate on Probuphine treatment of OUD in criminal justice system

Titan Pharmaceuticals (NASDAQ:TTNP) launched a pilot program in collaboration with the Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Titan’s Probuphine (buprenorphine)...

September 4, 2018

Developments

Urovant Sciences licenses gene therapy for overactive bladder

Closely-held Urovant Sciences licensed from Ion Channel Innovations global rights for an investigational gene therapy, hMaxi-K, for patients with overactive bladder (OAB) symptoms, who have failed oral pharmacologic...

August 28, 2018

Category - Developments

Subscribe